Modeling rett syndrome using human induced pluripotent stem cells

Tomoko Andoh-Noda, Michiko O. Inouye, Kunio Miyake, Takeo Kubota, Hideyuki Okano, Wado Akamatsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rett syndrome (RTT) is one of a group of neurodevelopmental disorders typically characterized by deficits in the X-linked gene MECP2 (methyl-CpG binding protein 2). The MECP2 gene encodes a multifunctional protein involved in transcriptional repression, transcriptional activation, chromatin remodeling, and RNA splicing. Genetic deletion of Mecp2 in mice revealed neuronal disabilities including RTT-like phenotypes and provided an excellent platform for understanding the pathogenesis of RTT. So far, there are no effective pharmacological treatments for RTT because the role of MECP2 in RTT is incompletely understood. Recently, human induced pluripotent stem cell (hiPSC) technologies have improved our knowledge of neurological and neurodevelopmental diseases including RTT because neurons derived from RTT-hiPSCs can be used for disease modeling to understand RTT phenotypes and to perform high throughput pharmaceutical drug screening. In this review, we provide an overview of RTT, including MeCP2 function and mouse models of RTT. In addition, we introduce recent advances in disease modeling of RTT using hiPSC-derived neural cells.

Original languageEnglish
Pages (from-to)544-550
Number of pages7
JournalCNS and Neurological Disorders - Drug Targets
Volume15
Issue number5
Publication statusPublished - 2016 May 1

Fingerprint

Rett Syndrome
Induced Pluripotent Stem Cells
Methyl-CpG-Binding Protein 2
RNA Splicing
Phenotype
X-Linked Genes
Preclinical Drug Evaluations
Chromatin Assembly and Disassembly
Transcriptional Activation

Keywords

  • Autism
  • Drug screening
  • Human induced pluripotent stem cells (hiPSCs)
  • Methyl-CpG binding protein 2 (MeCP2)
  • Neural differentiation
  • Rett syndrome

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Andoh-Noda, T., Inouye, M. O., Miyake, K., Kubota, T., Okano, H., & Akamatsu, W. (2016). Modeling rett syndrome using human induced pluripotent stem cells. CNS and Neurological Disorders - Drug Targets, 15(5), 544-550.

Modeling rett syndrome using human induced pluripotent stem cells. / Andoh-Noda, Tomoko; Inouye, Michiko O.; Miyake, Kunio; Kubota, Takeo; Okano, Hideyuki; Akamatsu, Wado.

In: CNS and Neurological Disorders - Drug Targets, Vol. 15, No. 5, 01.05.2016, p. 544-550.

Research output: Contribution to journalArticle

Andoh-Noda, T, Inouye, MO, Miyake, K, Kubota, T, Okano, H & Akamatsu, W 2016, 'Modeling rett syndrome using human induced pluripotent stem cells', CNS and Neurological Disorders - Drug Targets, vol. 15, no. 5, pp. 544-550.
Andoh-Noda T, Inouye MO, Miyake K, Kubota T, Okano H, Akamatsu W. Modeling rett syndrome using human induced pluripotent stem cells. CNS and Neurological Disorders - Drug Targets. 2016 May 1;15(5):544-550.
Andoh-Noda, Tomoko ; Inouye, Michiko O. ; Miyake, Kunio ; Kubota, Takeo ; Okano, Hideyuki ; Akamatsu, Wado. / Modeling rett syndrome using human induced pluripotent stem cells. In: CNS and Neurological Disorders - Drug Targets. 2016 ; Vol. 15, No. 5. pp. 544-550.
@article{9b404cf04e8b4bd4ba0ca9643f2aee9b,
title = "Modeling rett syndrome using human induced pluripotent stem cells",
abstract = "Rett syndrome (RTT) is one of a group of neurodevelopmental disorders typically characterized by deficits in the X-linked gene MECP2 (methyl-CpG binding protein 2). The MECP2 gene encodes a multifunctional protein involved in transcriptional repression, transcriptional activation, chromatin remodeling, and RNA splicing. Genetic deletion of Mecp2 in mice revealed neuronal disabilities including RTT-like phenotypes and provided an excellent platform for understanding the pathogenesis of RTT. So far, there are no effective pharmacological treatments for RTT because the role of MECP2 in RTT is incompletely understood. Recently, human induced pluripotent stem cell (hiPSC) technologies have improved our knowledge of neurological and neurodevelopmental diseases including RTT because neurons derived from RTT-hiPSCs can be used for disease modeling to understand RTT phenotypes and to perform high throughput pharmaceutical drug screening. In this review, we provide an overview of RTT, including MeCP2 function and mouse models of RTT. In addition, we introduce recent advances in disease modeling of RTT using hiPSC-derived neural cells.",
keywords = "Autism, Drug screening, Human induced pluripotent stem cells (hiPSCs), Methyl-CpG binding protein 2 (MeCP2), Neural differentiation, Rett syndrome",
author = "Tomoko Andoh-Noda and Inouye, {Michiko O.} and Kunio Miyake and Takeo Kubota and Hideyuki Okano and Wado Akamatsu",
year = "2016",
month = "5",
day = "1",
language = "English",
volume = "15",
pages = "544--550",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Modeling rett syndrome using human induced pluripotent stem cells

AU - Andoh-Noda, Tomoko

AU - Inouye, Michiko O.

AU - Miyake, Kunio

AU - Kubota, Takeo

AU - Okano, Hideyuki

AU - Akamatsu, Wado

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Rett syndrome (RTT) is one of a group of neurodevelopmental disorders typically characterized by deficits in the X-linked gene MECP2 (methyl-CpG binding protein 2). The MECP2 gene encodes a multifunctional protein involved in transcriptional repression, transcriptional activation, chromatin remodeling, and RNA splicing. Genetic deletion of Mecp2 in mice revealed neuronal disabilities including RTT-like phenotypes and provided an excellent platform for understanding the pathogenesis of RTT. So far, there are no effective pharmacological treatments for RTT because the role of MECP2 in RTT is incompletely understood. Recently, human induced pluripotent stem cell (hiPSC) technologies have improved our knowledge of neurological and neurodevelopmental diseases including RTT because neurons derived from RTT-hiPSCs can be used for disease modeling to understand RTT phenotypes and to perform high throughput pharmaceutical drug screening. In this review, we provide an overview of RTT, including MeCP2 function and mouse models of RTT. In addition, we introduce recent advances in disease modeling of RTT using hiPSC-derived neural cells.

AB - Rett syndrome (RTT) is one of a group of neurodevelopmental disorders typically characterized by deficits in the X-linked gene MECP2 (methyl-CpG binding protein 2). The MECP2 gene encodes a multifunctional protein involved in transcriptional repression, transcriptional activation, chromatin remodeling, and RNA splicing. Genetic deletion of Mecp2 in mice revealed neuronal disabilities including RTT-like phenotypes and provided an excellent platform for understanding the pathogenesis of RTT. So far, there are no effective pharmacological treatments for RTT because the role of MECP2 in RTT is incompletely understood. Recently, human induced pluripotent stem cell (hiPSC) technologies have improved our knowledge of neurological and neurodevelopmental diseases including RTT because neurons derived from RTT-hiPSCs can be used for disease modeling to understand RTT phenotypes and to perform high throughput pharmaceutical drug screening. In this review, we provide an overview of RTT, including MeCP2 function and mouse models of RTT. In addition, we introduce recent advances in disease modeling of RTT using hiPSC-derived neural cells.

KW - Autism

KW - Drug screening

KW - Human induced pluripotent stem cells (hiPSCs)

KW - Methyl-CpG binding protein 2 (MeCP2)

KW - Neural differentiation

KW - Rett syndrome

UR - http://www.scopus.com/inward/record.url?scp=84974697700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974697700&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 544

EP - 550

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 5

ER -